RNAi Therapeutics Market Analysis And Forecast To 2032: Type (Small Interfering RNAS, Microrna), Application (Genetic Disorder, Oncology, Neurodegenerative Disorder, Cardiovascular Disorder, Respiratory Disorder, Neurodegenerative Disorders, Renal Disease

The global RNAi Therapeutics Market was valued at USD 1.4 Billion in 2021 and it is anticipated to grow up to USD 3.8 Billion by 2031, at a CAGR of 10.4% during the forecast period.

A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.

Market Trends and Drivers

Rising cases of chronic diseases

The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.

Increasing collaborative activities

The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals' rapidly growing pipeline of investigational RNAi therapeutics based on the company's proprietary Targeted RNAi Molecule (TRiMTM) platform." In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.

Market Restraints and Challenges

High investment and strict regulations

FDA drug approval rates have been declining in recent years. Obtaining FDA approval for a new drug has become extremely difficult. It has approved fewer than half as many new drugs in 2016 (19 so far) as it did in 2015 (45 total) and 2014. (41 total). As a result, despite large investments, the number of innovative drugs manufactured has decreased. The FDA cites manufacturing standards and other compliance issues as the primary causes of this downward trend. This can hamper the growth of RNAi therapeutics, especially since miRNAs and siRNAs fall into the relatively new field of genetic medicine, which may necessitate more intensive clinical trials.

This RNAi therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the RNAi therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

The report analyses the global RNAi Therapeutics Market based on type, application, route of administration, and region.
Global RNAi Therapeutics Market by Type
By type, the market is segmented into Small Interfering RNAS, and Microrna. The on-premise segment held the largest revenue share of more than 62.0% in 2021. Small-interfering RNA (siRNA), synthetic double-stranded RNA consisting of approximately 21 base pairs, suppresses problematic target genes in a sequence-specific manner via inherent RNA interference (RNAi) processing. As a result, siRNA offers a potential strategy for treatment of many human diseases. Small-interfering RNA (siRNA), synthetic double-stranded RNA consisting of approximately 21 base pairs, suppresses problematic target genes in a sequence-specific manner via inherent RNA interference (RNAi) processing. As a result, siRNA offers a potential strategy for treatment of many human diseases.
Global RNAi Therapeutics Market by Application
By application, the RNAi Therapeutics Market is classified into Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurodegenerative Disorders, Genetic Disorders, and Others. Advancements in technologies, such as NGS and microarray, are major drivers of the industry. The decline in sequencing prices has driven attention to the testing of rare diseases. In addition, the rising demand for early & rapid diagnosis is expected to foster the growth of the market. Furthermore, the critical role of translational research & genomic technologies to enhance the analysis and identification of novel mutations is expected to contribute to the industry growth. With more translational research activities in this area, the implementation of genetic testing in disease diagnostics is anticipated to witness high growth during the forecast period.
Global RNAi Therapeutics Market by Route of Administration
The Route of Administration, it is segmented into Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, and Others. As per the data published by the Global Asthma Network (GAN) in “The Global Asthma Report 2014”, asthma affects nearly 334 million people worldwide. The substantial increase in prevalence and incidence of respiratory diseases has led to an increase in the patient population, which has in turn increased the demand for these systems. This consequent increase in demand is estimated to drive growth over the coming years.

Geographical Analysis of Global RNAi Therapeutics Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate the market. This is due to the high usage of antisense and RNAi therapeutics such as Spinraza offered by Biogen Inc., Onpattro and Givlaari offered by Alnylam Pharmaceuticals, Inc., and others in the region. In addition, other factors that contribute to the growth of the market in the region include the availability of advanced antisense and RNAi therapeutics. Furthermore, the presence of well-established healthcare infrastructure in the region leads to a surge in early screening of rare diseases which in turn leads to a surge in demand for antisense and RNAi therapeutics. For instance, Cure SMA is a non-profit organization dedicated to promoting and supporting research related to spinal muscular atrophy. Furthermore, in June 2021, Cure SMA reported that 85% of newborns in the United States were screened for spinal muscular atrophy.

In addition, in August 2022, Cure SMA announced the addition of 9 new spinal muscular atrophy screening centers to its Care Center Network. In addition, currently, there are 27 such care centers in this network across the United States. Thus, this leads to a surge in early screening in the region which in turn leads to a surge in demand for antisense and RNAi therapeutics. Therefore, owing to the previously mentioned factors the growth of the market studied is anticipated in the North America Region.

Major Players in the Global RNAi Therapeutics Market

The key players in the RNAi Therapeutics Market Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.), among others.

COVID-19 Impact

The COVID-19 pandemic is expected to play an emphasized part in propelling the growth of the RNAi Therapeutics market. Since the outbreak, the global payment industry has evolved rapidly owing to the rise in the use of digital payment methods among people as well as digital transformation worldwide. In line with this, the need for providing digital financial services to customers has increased among the banks, which thereby has created growth opportunities. Thus, creating the need for implementing encryption software to secure customers’ data such as debit/credit numbers, and date of birth.

Recent Developments

• In December 2021, Novartis AG received Food and Drug Administration (FDA) approval for Leqvio (inclisiran). Furthermore, Leqvio is a small interfering RNA (siRNA) therapy approved for lowering low-density lipoprotein cholesterol (LDL).
• In December 2021, AstraZeneca plc and Ionis Pharmaceuticals entered into global development and commercialization agreement for eplontersen, an antisense investigational medicine. Furthermore, eplontersen is currently being studied in phase II of clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN).
• In July 2021, Alnylam Pharmaceuticals, Inc. and PeptiDream Inc. entered into a licensing and collaboration agreement. Furthermore, the agreement is aimed at the discovery and development of peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.

Frequently Asked Questions

Q1. How big is the biliary stents market?Ans. The global RNAi Therapeutics Market was valued at USD 1.4 Billion in 2021 and it is anticipated to grow up to USD 3.8 Billion by 2032, at a CAGR of 10.4% during the forecast period.Q2. What is the RNAi Therapeutics Market growth rate?Ans. The growth rate of the RNAi Therapeutics Market is 10.4%Q3. Which region holds a major market share for the market?Ans. North America holds a major market share of the RNAi Therapeutics Market in 2021.Q4. Which segment accounted for the largest RNAi Therapeutics Market share?Ans. By route of administration, the Cloud Encryption segment accounted for the largest RNAi Therapeutics Market share.Q5. Who are the key players in the kidney stones management market?Ans. The global RNAi Therapeutics Market report includes players such as Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.) among others.Q6. What are the factors driving the RNAi Therapeutics Market growth?Ans. The major factors driving the growth of the market are the increasing collaboration activities between drug distribution companies and contract research organizations (CROs).Q7. What are the key growth strategies of RNAi Therapeutics Market players?Ans. The key growth strategies of RNAi Therapeutics Market players are product launch and product approval.Q8. Which region will provide more business opportunities for the RNAi Therapeutics Market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the RNAi Therapeutics Market during the forecast period.


Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.